Aethlon Medical Advances Oncology Trial, Cuts Costs Amid Cash Crunch
Event summary
- Cohort 2 of Australian oncology trial progressing with 9-18 patients evaluating Hemopurifier's safety and dosing.
- Operating expenses down 26.9% year-to-date, but Q3 loss widens to $2.06M from $1.81M.
- Cash balance at $7.0M as of December 31, 2025, with no clear runway extension.
- Hemopurifier compatibility testing with Stavro's SLAMB system for simplified blood treatment.
- Long COVID research published on bioRxiv, submitted for peer review, expanding potential indications.
The big picture
Aethlon's cost-cutting measures are buying time for its Hemopurifier platform, but the company's cash position remains precarious. The ongoing Australian trial and expanding research into Long COVID and other diseases highlight the device's potential as a multi-indication therapeutic, though commercialization remains distant. The biotech sector's focus on cost-efficient clinical development will be critical for Aethlon's survival.
What we're watching
- Clinical Execution
- Whether Cohort 2 can demonstrate sufficient safety and dosing data to advance the Hemopurifier's oncology application.
- Financial Sustainability
- The pace at which Aethlon can extend its cash runway beyond the current $7.0M balance.
- Therapeutic Expansion
- How quickly Aethlon can validate additional indications like Long COVID and other EV-associated diseases.
Related topics